Vaccinex Inc

NASDAQ:VCNX  
2.10
+0.03 (+1.45%)
Earnings Announcements

Vaccinex Ends Q3 With Cash And Cash Equivalents Of $17.1 Million

Published: 11/13/2020 13:13 GMT
Vaccinex Inc (VCNX) - Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Vaccinex Inc - Additional Data From Signal Huntington's Disease (hd) Trial Support Continued Development in Hd and in Alzheimer's Disease.
Vaccinex Inc - Ended Quarter With Cash and Cash Equivalents of $17.1 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.38

Next Quarter Revenue Guidance is expected to be $0.19 Million
Next Quarter EPS Guidance is expected to be -$0.43

More details on our Analysts Page.